Transcription of Brovana Approved Labeling Text
{{id}} {{{paragraph}}}
Example: air traffic controller
Brovana Approved Labeling Text
DOSAGE FORMS AND STRENGTHS. Inhalation Solution (unit-dose vial for nebulization): 15 mcg/2 mL solution (3). CONTRAINDICATIONS. Brovana Inhalation Solution is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product. (4). Use of a LABA, including Brovana Inhalation Solution, without an inhaled 15 mcg*/2 mL corticosteroid is contraindicated in patients with asthma. (4). *potency expressed as arformoterol WARNINGS AND PRECAUTIONS. LABA as monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events. ( ). PRESCRIBING INFORMATION Do not initiate Brovana Inhalation Solution in acutely deteriorating patients . ( ). Do not use for relief of acute symptoms. Concomitant short-acting beta2-agonists can be used as needed for acute relief. ( ). Do not exceed the recommended dose.
acting beta2-agonist and instruct the patient how it should be used. Increasing inhaled beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated. COPD may deteriorate acutely over a period of hours or chronically over several days or longer.
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: